SOCRA - Society of Clinical Research Associates Society of Clinical Research Associates Essential Study Documents 1 — Questions and Answers
Question 1: FDA Form 1572 (Statement of Investigator) legally binds an investigator to which of the following commitments?
- Submitting annual IND progress reports to the FDA on behalf of the sponsor
- Conducting the study in accordance with the protocol and applicable regulations, and allowing FDA inspections (Correct answer)
- Providing financial disclosure for all study-related payments received from the sponsor
- Certifying that all subjects have provided written informed consent before data analysis begins
Correct answer: Conducting the study in accordance with the protocol and applicable regulations, and allowing FDA inspections
FDA Form 1572 is a regulatory commitment by the principal investigator to conduct the trial per the protocol and applicable regulations (21 CFR Parts 312/50/54), maintain adequate records, and permit FDA access to those records. It is not an annual report form, a financial disclosure form, or a post-enrollment certification.
Question 2: According to ICH E6(R2), the minimum set of essential documents that should be on file for a clinical trial is defined in which section?
- Section 4 — Investigator responsibilities
- Section 5 — Sponsor responsibilities
- Section 8 — Essential documents for the conduct of a clinical trial (Correct answer)
- Section 6 — Clinical trial protocol and amendments
Correct answer: Section 8 — Essential documents for the conduct of a clinical trial
ICH E6(R2) Section 8 specifically catalogues the essential documents required before, during, and after clinical trial conduct. These documents collectively enable evaluation of trial conduct and data quality. Sections 4, 5, and 6 address investigator/sponsor responsibilities and protocol requirements, not the essential document inventory.
Question 3: What is the primary purpose of a Delegation of Authority (DoA) log at an investigational site?
- To record all protocol deviations attributable to individual staff members
- To document which trial-related tasks the principal investigator has assigned to qualified team members (Correct answer)
- To serve as the site's training curriculum for Good Clinical Practice compliance
- To list all vendors and central laboratories contracted for the study
Correct answer: To document which trial-related tasks the principal investigator has assigned to qualified team members
The DoA log records which specific study tasks have been formally delegated by the PI to named, qualified team members. It demonstrates that only trained, competent staff perform delegated duties and is reviewed by monitors and auditors to confirm regulatory compliance. It is not a deviation record, training plan, or vendor list.
Question 4: Under ICH E6(R2), how frequently must the Investigator's Brochure (IB) be reviewed and updated?
- Every six months, regardless of whether new safety data are available
- At least once per year, or more often if clinically significant new information emerges (Correct answer)
- Only at the end of each study phase (e.g., Phase I to Phase II transition)
- Upon every protocol amendment that changes the primary endpoint
Correct answer: At least once per year, or more often if clinically significant new information emerges
ICH E6(R2) requires the IB to be reviewed at least annually; if new information that significantly affects subject safety or trial conduct becomes available, an updated IB must be issued sooner. The annual minimum ensures investigators have current benefit–risk information, independent of protocol amendments or phase transitions.
Question 5: Which essential document must be reviewed, signed, and dated by a subject (or legally authorized representative) before any study-specific screening procedure may be performed?
- The Clinical Study Report signature page
- The Serious Adverse Event report form
- The Informed Consent Form (ICF) (Correct answer)
- The Case Report Form (CRF) demographic page
Correct answer: The Informed Consent Form (ICF)
Obtaining a signed and dated ICF prior to any study-specific procedures is a fundamental ethical and regulatory requirement (ICH E6, 21 CFR Part 50). The CSR signature page is completed at trial end, SAE forms are used after enrollment, and CRF demographic pages capture data after consent is already obtained.
Question 6: Why must site-specific normal laboratory ranges (reference ranges) be collected and maintained in the Trial Master File?
- They replace the need for a central laboratory manual when local labs are used
- They allow the sponsor to convert local units to SI units in the clinical database
- They enable accurate determination of whether laboratory results are clinically notable or constitute potential adverse events (Correct answer)
- They fulfill the IRB's annual continuing-review data submission requirement
Correct answer: They enable accurate determination of whether laboratory results are clinically notable or constitute potential adverse events
Site-specific normal laboratory ranges are essential for contextualizing subject lab values: without knowing the local lab's reference intervals, neither investigators nor monitors can reliably classify a result as normal, abnormal-not-clinically-significant, or an adverse event. They do not replace lab manuals, serve unit conversion, or satisfy IRB reporting requirements.
SOCRA - Society of Clinical Research Associates Society of Clinical Research Associates Essential Study Documents 1
FDA Form 1572 (Statement of Investigator) legally binds an investigator to which of the following commitments?